Search

Displaying results 1431 - 1440 of 10000 in total
  1. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. … Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.

  2. Indication

    AIDS-related Kaposi's Sarcoma

    go.drugbank.com/conditions/DBCOND0025353
    Drugs: Doxorubicin
    Synonyms: HIV disease resulting in Kaposi's sarcoma (disorder)
  3. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050 … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].

    Categories: Drugs Used in Diabetes, DPP-IV InhibitorsProducts: Linagliptin 1A Pharma 5 mg - Filmtabletten
  4. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    with first-line therapies, putting them in a risk for poor outcomes and creating a significant clinical challenge [A31818]. … Based on its tolerability and safety profile, remestemcel-L is a promising alternative to second-line immunosuppressive agents [A31818].

    Synonyms: Remestemcel-L
  5. Drug

    Clofedanol

    go.drugbank.com/drugs/DB04837
    ApprovedWithdrawn

    Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.

    Mixtures: Atuss Da, Atuss Da
  6. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries. … Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953]

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  7. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    [A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459] … being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.

  8. Indication

    Osteoarthritis of the Knee

    go.drugbank.com/conditions/DBCOND0032623
    Drugs: Diacerein · Diclofenac · Dimethyl sulfone · Duloxetine · Glucosamine
    Synonyms: Osteoarthritis in the Knee, Osteoarthritis in the Knee Joint
  9. Drug

    Sulpiride

    go.drugbank.com/drugs/DB00391
    ApprovedWithdrawn

    Sulpiride first appeared in published literature in 1967. … [A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

    Synonyms: N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide, N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamideCategories: Dopamine D2 Receptor Antagonists
  10. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556].

    Categories: N-methyl-D-aspartate Receptor AntagonistProducts: ZAHARME IR, MEMANTIN 1A PHARMA 10MG